Physician profile
Nathaniel Evans
NPI 1285780239
$186,698.53
in general payments reported to CMS, 2019-2025
13 companies · $47K in 2025
The $47K reported for 2025 was more than what 97% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $34K · 2021: $30K · 2022: $9,543 · 2023: $14K · 2024: $26K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Education: $15K · Travel and Lodging: $14K · Consulting Fee: $9,881 · Food and Beverage: $4,589 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,860.00 |
| Education | $14,500.00 |
| Travel and Lodging | $13,860.26 |
| Consulting Fee | $9,881.00 |
| Food and Beverage | $4,589.35 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $87,385.14 | 2019-2025 | Da Vinci Sp, Da Vinci Surgical System |
| Merck Sharp & Dohme LLC | $43,599.84 | 2024-2025 | Keytruda |
| Covidien Lp | $37,644.37 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $12,462.64 | 2021-2025 | Imfinzi, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $2,667.38 | 2022 | |
| Genentech USA, INC. | $2,414.16 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $124.07 | 2019 | |
| Medtronic, INC. | $123.17 | 2024 | Valiant Captivia |
| Abbott Laboratories | $116.00 | 2022 | |
| Davol INC. | $83.49 | 2024 | Phasix Mesh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.47 | 2021-2022 | |
| Glaxosmithkline, LLC. | $20.06 | 2020 | |
| Lilly USA, LLC | $16.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.